EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE

被引：0
|
作者：
Papayannidis, C. [1 ]
Iacobucci, I. [1 ]
Soverini, S. [1 ]
Paolini, S. [1 ]
Clissa, C. [1 ]
Parisi, S. [1 ]
Abbenante, M. C. [1 ]
Colarossi, S. [1 ]
Gnani, A. [1 ]
Lonetti, A. [1 ]
Ferrari, A. [1 ]
Testoni, N. [1 ]
Amabile, M. [1 ]
Ottaviani, E. [1 ]
Curti, A. [1 ]
Guadagnuolo, V. [1 ]
Baccarani, M. [1 ]
Martinelli, G. [1 ]
机构：
[1] Inst Hematol, Bologna, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0611
引用
收藏
页码：257 / 257
页数：1
相关论文
共 50 条
  • [31] Comparison of clinical efficacy between first-generation and second-generation tyrosine kinase inhibitors based regimen in the treatment of patients with BCR-ABL positive acute lymphoblastic leukemia
    刘莹
    China Medical Abstracts (Internal Medicine), 2019, 36 (04) : 230 - 230
  • [32] MINIMAL RESIDUAL DISEASE MONITORING IN PATIENTS WITH PHILADELPHIA-CHROMOSOME POSITIVE (PH1) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATED WITH THE COMBINATION OF HYPERCVAD AND A TYROSINE KINASE INHIBITOR
    Ravandi, F.
    Thomas, D.
    O'Brien, S.
    Faderl, S.
    Jorgensen, J.
    Luthra, R.
    Kebriaei, P.
    Garris, R.
    Cortes, J.
    Kantarjian, H.
    ANNALS OF ONCOLOGY, 2011, 22 : 223 - 224
  • [33] Blinatumomab plus Tyrosine Kinase Inhibitors in the Treatment of Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Patients - Clinical Efficacy and Peripheral Blood Lymphocytes Subpopulations Kinetics
    Sokolov, Andrey N.
    Parovichnikova, Elena N.
    Troitskaya, Vera V.
    Galtseva, Irina V.
    Davidova, Julia O.
    Kapranov, Nikolai M.
    Obukhova, Tatiana N.
    Savchenko, Valeri G.
    BLOOD, 2016, 128 (22)
  • [34] The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia
    Wu, Xiaoxia
    Lu, Shenqi
    Zhang, Xinhui
    Yang, Zhen
    Sun, Aining
    Wu, Depei
    Zhou, Huifen
    Miao, Miao
    CANCER MEDICINE, 2024, 13 (17):
  • [35] Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
    Jabbour, Elias
    DerSarkissian, Maral
    Duh, Mei Sheng
    McCormick, Nora
    Cheng, Wendy Y.
    McGarry, Lisa J.
    Souroutzidis, Ariadne
    Huang, Hui
    O'Brien, Susan
    Ravandi, Farhad
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (04): : 257 - 265
  • [36] Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant
    Samra, Bachar
    Kantarjian, Hagop M.
    Sasaki, Koji
    Alotaibi, Ahmad S.
    Konopleva, Marina
    O'Brien, Susan
    Ferrajoli, Alessandra
    Garris, Rebecca
    Nunez, Cesar A.
    Kadia, Tapan M.
    Short, Nicholas J.
    Jabbour, Elias
    ACTA HAEMATOLOGICA, 2021, 144 (03) : 285 - 292
  • [37] Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors
    Cohen, Gordon
    Annesley, Colleen E.
    Rau, Rachel E.
    Kelley, Shannon
    Magoon, Daniel
    Brown, Patrick
    BLOOD, 2015, 126 (23)
  • [38] Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
    Iacobucci, Ilaria
    Lonetti, Annalisa
    Messa, Francesca
    Cilloni, Daniela
    Arruga, Francesca
    Ottaviani, Emanuela
    Paolini, Stefania
    Papayannidis, Cristina
    Piccaluga, Pier Paolo
    Giannoulia, Panagiota
    Soverini, Simona
    Amabile, Marilina
    Poerio, Angela
    Saglio, Giuseppe
    Pane, Fabrizio
    Berton, Giorgio
    Baruzzi, Anna
    Vitale, Antonella
    Chiaretti, Sabina
    Perini, Giovanni
    Foa, Robin
    Baccarani, Michele
    Martinelli, Giovanni
    BLOOD, 2008, 112 (09) : 3847 - 3855
  • [39] No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)
    Iglesias, Lilian
    Mukherjee, Sudipto
    Nazha, Aziz
    Advani, Anjali S.
    Gerds, Aaron T.
    Carraway, Hetty E.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Majhail, Navneet S.
    Sekeres, Mikkael A.
    BLOOD, 2017, 130
  • [40] Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK
    Byrne, Jenny
    Ewing, Joanne
    Mead, Adam J.
    Oakervee, Heather
    Campbell, Gavin
    Amott, Ian
    Goringe, Andrew
    Heartin, Earnest
    Dimitriadou, Evangelia
    Pamphlett, Ian
    Arami, Siamak
    Neelakantan, Pratap
    Frewin, Rebecca
    Pillai, Srinivas
    De lavallade, Hugues
    Cross, Nicholas C. P.
    Thompson, Michael
    BLOOD, 2019, 134
12345